← Back to Clinical Trials
Recruiting NCT06740071

NCT06740071 The Application of Somatosensory Interactive Pelvic Floor Muscle Training for Stress Urinary Incontinence in Men Underwent Radical Prostatectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06740071
Status Recruiting
Phase —
Sponsor The University of Hong Kong
Condition Prostate Cancer (Post Prostatectomy)
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2023-05-01
Primary Completion 2027-04

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
somatosensory interactive pelvic floor muscle trainingpelvic floor magnetic stimulation therapystandard pelvic floor muscle training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2023-05-01 with a primary completion date of 2027-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study aims to compare the efficacy of different pelvic floor muscle training (PFMT) modes on improving urinary incontinence (UI) recovery in prostate cancer (PCa) patients after radical prostatectomy (RP). The methods being compared include standard PFMT (S-PFMT) , a somatosensory interactive PFMT (SI-PFMT, an enhanced PFMT) , and a standard PFMT combined with pelvic floor muscle magnetic stimulation (S-PFMT+MS). Eligible participants are randomized into either of the groups to receive different modalities of post-operative PFMT. Subjects in the S-PFMT group received traditional verbal instructions and paper-based educational materials. For the SI-PFMT group, an interactive experiential education model was adopted. First, an educational video introduced the importance and basic information of postoperative PFMT. Then, synchronized PFMT guidance through a combination of audio and video would be used. Subjects assigned to the S-PFMT+MS group, on the basis of traditional verbal and paper-based education, pelvic floor magnetic stimulation therapy was applied using a pelvic floor magnetic stimulator, operated by the same experienced rehabilitation physician. Self administered questionnaires and 1-hour pad test would be used to assess the treatment outcomes at 1, 3, and 6 months postoperatively.

Eligibility Criteria

Inclusion Criteria: * PCa patients aged 18 to 85 years who had undergone laparoscopic radical prostatectomy (RP) Exclusion Criteria: * patients currently participating in other clinical trials and those unable to cooperate with study interventions and follow-up procedures due to specific factors

Contact & Investigator

Central Contact

Research Assistant, BSc

✉ stac@hku.hk

📞 852-22554852

Frequently Asked Questions

Who can join the NCT06740071 clinical trial?

This trial is open to male participants only, aged 18 Years or older, up to 85 Years, studying Prostate Cancer (Post Prostatectomy). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06740071 currently recruiting?

Yes, NCT06740071 is actively recruiting participants. Contact the research team at stac@hku.hk for enrollment information.

Where is the NCT06740071 trial being conducted?

This trial is being conducted at Shanghai, China, Hong Kong, Hong Kong.

Who is sponsoring the NCT06740071 clinical trial?

NCT06740071 is sponsored by The University of Hong Kong. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology